Jubilant Pharmova's US Unit to Invest $300 Million by FY28, Doubling Sterile Injectable Capacity

Jubilant Pharmova Limited announced that its North American subsidiary, Jubilant HollisterStier LLC (JHS), has launched a new sterile fill and finish production line at its Spokane, Washington, facility in the United States. The milestone was achieved with the successful production of the first commercial batch, marking the start of revenue generation from the new line.

Expansion and Strategic Impact

The new high-speed isolator-based line adds 50% additional capacity to the Spokane facility and represents an investment of $132 million. It features advanced isolator technology designed to ensure enhanced sterility, precision, and throughput while meeting the highest international regulatory standards.

This expansion forms a key part of JHS’s multi-phase growth strategy aimed at doubling its total sterile injectable manufacturing capacity once the upcoming fourth line is also commissioned. The company said this initiative strengthens its role in supporting US domestic pharmaceutical manufacturing, supply chain resilience, and reduced dependency on offshore production.

Leadership Remarks

As per the exchange filings, Chris Preti, CEO of CDMO Sterile Injectables at JHS, said, “Launching our third line is not just a milestone, but a defining moment in our journey. With this expansion, we are reinforcing our commitment to growth, technological excellence, and community development in Spokane. The new line will create hundreds of jobs, support the US healthcare system, and help us meet growing demand from global innovator companies.”

Preti further said, "This will bring an additional 50% of capacity in the US that is available now and then, the additional investment, totalling $300 million in all, will actually be completed by the end of fiscal year 2028, which will bring on another 50% of additional capacity.”

Company Background

JHS partners with five of the top 20 global pharmaceutical companies and maintains a 92% customer retention rate. It operates facilities in Spokane, Washington and Montréal, Québec, providing sterile fill-finish, lyophilisation, and ophthalmic manufacturing services for clients across more than 140 countries.

Read More: Jubilant Group Block Deal: Promoters to Offload Stakes Worth ₹2,165 Crore!

Jubilant Pharmova Share Price Performance 

As of October 10, 2025, at 12:15 PM, Jubilant Pharmova share price is trading at ₹1,108.50 per share, reflecting a surge of 0.96% from the previous closing price.

Conclusion

The commissioning of the new line marks a major step forward in Jubilant HollisterStier’s US expansion strategy, reinforcing its position as a trusted global partner in sterile manufacturing. The investment underscores Jubilant Pharmova’s long-term commitment to innovation, quality, and strengthening pharmaceutical infrastructure worldwide.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.